Lupus

Anne Winkler, MD, discusses the importance of patient-reported outcome measures when treating her patients with lupus.

Anne Winkler, MD, discusses her upcoming CCR East presentation, “Targeting Lupus Nephritis.”

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.

The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.

Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.

Shanthini Kasturi, MD, MS, discusses the importance of patient-reported outcome measures to optimize the care of patients with systemic lupus erythematosus.

Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.

Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.

Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.

Disease flares in systemic lupus erythematosus are associated with damage. However, the impact of flares on health-related quality of life have not been analyzed.

Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.

Iberdomide, a high-affinity cereblon modulator, works by affecting leukocyte development and autoimmunity.

With several targeted therapies demonstrating positive trial results in lupus nephritis, the treatment paradigm appears to be shifting.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

More than 50% of patients with classified SLE at Washington University’s Lupus Clinic exhibit clinically meaningful and persistent depression and anxiety symptoms over time.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

The treat-to-target paradigm has been utilized in RA and other diseases, but not yet lupus. Treat-to-target guidelines in lupus could be complex, but are needed.

The development of biologic therapies and other treatments for lupus remains a challenge, but anti-interferon agents that are in development could turn things around.

Belimumab has been a ground-breaking therapy for patients with systemic lupus erythematosus. In this op-ed, Paul Sufka, M.D., reviews recent studies on belimumab which could lead to new uses.

Belimumab combined with standard of care continues to show positive improvements for patients with systemic lupus erythematosus.

Anemia could increase the prevalence of restless legs syndrome in patients with lupus.

A Phase II trial of a new monoclonal antibody drug shows promise for a potential new treatment for lupus.

Despite missing the primary endpoint, trial of repository corticotropin shows improved key measures.

A consensus definition of a lupus low disease activity state appears to predict improved outcomes among patients with systemic lupus erythematosus.

Lower doses of the fusion protein atacicept do not prevent flares in patients with moderate-to-severe systemic lupus erythematosus, study shows

New methodologies for clinical trials in lupus are in development. If successful, the next decade could see the development of new targeted therapies for lupus.

Teens and young adults with systemic lupus erythematosus view the disease as constraining their choices and forcing them to make sacrifices, new research finds.